Introduction
Combination antiretroviral therapy (ART) suppresses HIV RNA in the cerebrospinal fluid (CSF) in most patients but persistently detectable HIV RNA during ART has been linked to the risk for HIV-associated neurocognitive disorder (HAND) 1 and depression. 2 For example, early analyses identified that higher HIV RNA concentrations in CSF, but not in plasma, were associated with HAND. [3] [4] [5] Specifically, elevated HIV RNA concentrations in CSF predicted impairment in the domains of learning, motor, attention, and working memory function. 6 Analyses in the era of potent combination ART, however, have generally found weakened associations between HIV RNA con centration in CSF and neurocognitive outcomes 7 .
HIV RNA in CSF might also be important for other reasons. First, low concentrations of HIV RNA in CSF could lead to inflammation in the CNS. 8 Second, HIV RNA in CSF could indicate viral escape in the CNS, which occurs in about 5% of otherwise effectively treated adults and can be associated with neurological symptoms. 9, 10 Third, failure to suppress HIV RNA fully in CSF could lead to development of drug-resistance mutations and limit the potential for a functional HIV cure. Finally, HIV RNA concentrations in CSF might reflect those in brain tissue and thus might be useful for studies that are focused on eradicating HIV.
Although many studies of HIV RNA in CSF have been published (appendix), they were either cross-sectional in design or had relatively modest sample sizes. Large, longitudinal analyses are better suited for inferring causality than smaller, cross-sectional ones. An observational cohort, CNS HIV AntiRetroviral Therapy Effects Research (CHARTER), sampled CSF in a large number of volunteers over several years, enabling such analyses. 6 Our objective was to understand the correlates of HIV RNA concentration in CSF over time in adults who are taking ART. We hypothesised that multiple characteristics, including HIV RNA in plasma and estimated drug distribution in the CNS, would be associated with HIV RNA concentration in CSF over time.
Methods

Study design
The CHARTER study is a six-site, prospective, observational study that was designed to comprehensively assess a representative clinical population of adults living with HIV in the USA. The six sites were in Baltimore (MD), Galveston (TX), New York (NY), St Louis (MO), San Diego (CA), and Seattle (WA). All sites were based at US academic medical centres and were selected by a competitive, peer-review process. Participants were recruited from the clinics located at these US academic medical centres and via community centres, advocacy groups, and community advisory boards.
Study population
We analysed data from all participants in the US CHARTER cohort who underwent at least 3 semi-annual assessments between Sept 4, 2003, and Sept 14, 2010;  reported use of ART at all visits; successfully underwent venous and lumbar puncture; and had HIV RNA concentration measured in collected blood and CSF.
The Institutional Review Board at each site approved all study procedures and all participants provided written informed consent.
Procedures
Comprehensive neuromedical assessments were done, including medical and treatment history, physical examination, and venous and lumbar puncture. Participants were assessed by investigators or trained study personnel. All participants underwent all assessments at each visit with the exception of lumbar puncture (not all participants consented) and neuroimaging (done in only a subgroup by design).
ART drug distribution into the CNS was estimated by the CNS penetration-effectiveness method. 11 ART nonadherence was estimated by self-report of taking fewer than 95% of doses in the 4 days before assessment (AIDS Clinical Trials Group 4-day method). HIV RNA was quantified by commercial RT-PCR (Amplicor For the CHARTER study website see https://charternntc.org
Research in context
Evidence before this study Before doing this study, we considered the extent of previously published data on the correlates of HIV RNA concentrations in cerebrospinal fluid (CSF) in adults living with HIV and taking combination antiretroviral therapy (ART). We searched PubMed for analyses of longitudinal data published between Jan 1, 2002, and Dec 31, 2017, using terms "HIV RNA" AND "cerebrospinal fluid" AND "antiretroviral" AND "adult" AND "longitudinal" NOT "opportunistic" NOT "monotherapy". The results of our search are summarised in the appendix. In brief, many of these longitudinal studies focused on the change in HIV RNA in CSF in response to ART and some identified correlates of HIV RNA in CSF over time, which included HIV RNA in plasma, CD4 cell count, duration of ART, and characteristics of the ART regimen. A separate, large analysis from our group focused solely on cross-sectional data and confirmed some of these correlates of HIV RNA in CSF (eg, HIV RNA in plasma and ART characteristics) and also identified other contributors (eg, race and depression).
Added value of this study
The publications we found in our search (appendix) have a mean sample size of 41 participants. By contrast, this Article summarises longitudinal data from more than 2200 lumbar puncture samples from nearly ten times as many participants (n=401), which adds substantially to the existing HIV literature. In addition to confirming previous findings linking HIV RNA levels in CSF to HIV RNA levels in plasma, CSF leukocyte number, and ART drug characteristics (eg, number of neuroactive drugs), we found evidence of associations with CD4 and CD8 cell counts. This finding adds to mounting evidence linking the low ratio of these T-cell subsets to persistent immune dysfunction, reservoir size, and complications in adults living with HIV during ART.
Implications of all the available evidence
The longitudinal data in this Article strengthen existing data from previous small studies. With the increasing recognition that CSF viral escape occurs in about 5% of treated adults living with HIV, our findings might help identify patients at risk for CSF viral escape and other complications of the CNS in the clinic. The data could also have implications for efforts to eradicate HIV from the CNS.
See Online for appendix version 1.5, Roche Diagnostics, Indianapolis, IN, USA; lower limit of quantification 50 copies per mL). Other biomarkers (eg, CD4 cell count, electrolytes, complete blood count, and CSF leucocytes) were measured by routine clinical methods. Nadir CD4 cell count was defined as the lowest value of either self-reported count or study measurement. HIV-associated neurocognitive disorders were diagnosed according to the Frascati criteria. 12 All participants completed the Beck Depression Inventory and major depression was diagnosed by Diagnostic and Statistical Manual of Mental Disorders (DSM-IV) criteria.
Statistical analysis
Because all participants were taking ART, the distribution of HIV RNA in CSF was highly skewed with many tied, undetectable values. For this reason, HIV RNA concentration in CSF was analysed by two methods. First, we analysed HIV RNA in CSF as a binary variable (greater than the lower limit of quantification [detectable] or less than or equal to the lower limit of quantification [undetectable]) using longitudinal modelling with logistic regression. Then, we analysed HIV RNA in CSF as a continuous variable and accounting for censoring below the limit of detection by a published method 13 using linear mixed models. We screened demographic, HIV disease, treatment, and CSF characteristics, for inclusion in multivariate models by using individual mixed effects models. Candidate covariates were selected for multivariate analysis using an α of 0·10. Multivariate analysis was then done, also using longitudinal mixed effects logistic regression. When the distribution of independent variables were highly skewed, we transformed them to reduce skewness (eg, log 10 transformation of plasma HIV RNA and square-root transformation of cell counts). Regression-derived estimates were converted to odds ratios (ORs) to ease interpretation. For this same reason, ORs were adjusted for plasma HIV RNA (per 1 log 10 copies per mL) and cell counts (per 5 square-root cells). Correlation within participants was modelled via a participant-specific random effect. We built multivariate models with backward elimination with the goal of deriving a concise combination of predictors based on maximal explanatory value after eliminating variables that did not contribute to a better fit. Data were analysed using R statistical software program (version 3.1.1), including the Imec package.
Role of the funding source
The funder of the study played no role in study design, data collection, data analysis, data interpretation, or writing of the report. The corresponding author and the principal investigator had full access to all the data in the study and had final responsibility for the decision to submit for publication.
Results
At the time of analysis, 2207 assessments from 401 participants met the criteria for inclusion in this study. At first visit, participants were mostly middle-aged ( The mean duration of observation was 33·7 months (range 12-84). The mean number of lumbar punctures per subject was 5·3 (SD 3·0). All participants reported ART use at all visits. For all visits combined, the median duration of the current (ie, at the time of each visit) ART regimen was 18·0 months (IQR 7·6-34·2). 282 (70·3%) participants took ART regimens containing three drugs and 89 (22%) were taking their first regimen. HIV RNA concentrations were undetectable in plasma at 1444 (65·4%) of 2207 visits and in CSF at 1955 (88·6%) visits. When HIV RNA concentrations were detectable in plasma, the median value was 544 copies per mL (IQR 137-7265). When HIV RNA concentrations were detectable in CSF, the median value was 535 copies per mL (145-2498).
In analyses of the binary CSF HIV RNA (detectable vs undetectable) over time, screening analyses identified 15 variables that were associated with the outcome, the strongest of which was HIV RNA in plasma (OR 19·7, 95% CI 12·8-30·5; p<0·0001; figure; table 2). Variables that had p values greater than 0·10 with HIV RNA in CSF over time included sex, AIDS, current or lifetime depression, nadir CD4 cell count, duration of HIV infection, hepatitis C virus serostatus, and CSF erythrocyte number.
The best multivariate mixed effects model included six covariates (table 2). In descending order of effect size, the covariates of detectable HIV RNA in CSF were increased HIV RNA concentrations in plasma (OR 18·0 per 1 log 10 copies per mL, 95% CI 11·3-28·8), protease inhibitor use (3·26, 1·04-10·23), increased CSF leucocyte number (2·01 per 5 cells per µL, 1·61-2·39), decreased CD4 cell count (0·53 per 5 square-root cells per µL, 0·35-0·79), increased CD8 cell count (1·51 per 5 square-root cells per µL, 1·11-2·06), and decreased CNS penetration-effectiveness value (0·71 per unit, 0·56-0·92; model R²=0·22, p<0·0001).
When a binary transformation of CNS penetration effectiveness (CNS penetration effectiveness ≤ or > than the median value of 7) was included in the model instead of the untransformed value, protease inhibitor use was no longer significantly associated with HIV RNA in CSF over time.
In analyses of continuous HIV RNA in CSF that accounted for censoring below the lower limit of quantification (table 3) , the covariates were the same with four exceptions: CD8 cell count was not included in the best multivariate model, whereas increased CSF total protein, presence of addictive drug metabolites in urine, and black ethnicity were (model p<0·0001).
In secondary analyses, 148 (37%) of 401 participants had HIV RNA concentrations in plasma of 50 copies per mL or less at all visits. Nine (6%) of these participants had HIV RNA concentrations in CSF greater than 50 copies per mL at one or more visits, consistent with CSF viral escape. 9 These nine participants had a total of 63 visits and CSF viral escape occurred at 13 (21%) of them. Analyses of these 148 participants identified that CSF viral escape was associated with the presence of increased CSF leucocyte counts (p=0·035) across all visits. Limiting the analysis to the 63 visits from the nine participants who had a CSF viral escape event identified, we found that CSF viral escape was associated with both increased CSF leucocyte counts (p=0·029) and decreased CNS penetration-effectiveness values (p=0·022). 
Discussion
In this study, we modelled longitudinal data from 401 adults observed over an average of 2·5 years. We found that several viral, immune, and treatment variables were associated with HIV RNA in CSF over time. As expected, failure to suppress HIV RNA fully in plasma was the most influential factor in both linear and logistic models of HIV RNA in CSF. Fewer CD4 cells were also associated with HIV RNA in CSF over time in both models, consistent with the known link between low CD4 cell count and risk of HAND. 14 CD8 cells have not previously been clearly linked to HIV RNA in CSF, although reports 15 of CD8 encephalitis suggest at least an indirect link. The combination of low CD4 and high CD8 cell count is consistent with a persistently inverted CD4-to-CD8 ratio during ART, which might be a marker of immune senescence, 16 persistent T-cell activation, 17 and risk for non-AIDS comorbidities. 18 Our data suggest that a greater degree of CD4-to-CD8 ratio inversion also indicates increased risk for detectable HIV RNA in CSF during ART, which could increase the risk of CNS inflammation and vulnerability to HAND. 19 Of note, we did not find an association between CD8 cells and HIV RNA in CSF in analyses of continuous HIV RNA concentration in CSF that accounted for censoring below the lower limit of quantification. CSF leucocytes have long been linked to HIV RNA concentrations in CSF. 20 Our analysis independently validates this historical association and further supports a role for leucocyte migration in CSF viral escape. The combination of low CD4 cell counts and high CSF leucocyte counts is consistent with reports linking these factors with greater autonomous CNS production of HIV 21 and viral adaptation in CSF. 22 Decreased estimated effectiveness of ART in the CNS has previously been reported to correlate with HIV RNA in CSF in cross-sectional analyses. Our data lend further support to the role of ART in the pathogenesis of CSF viral escape. 9, 23 Although ART characteristics might be more clearly linked to the presence of HIV RNA in CSF, their relation to neurocognitive disorders remains controversial. 24 The inclusion of both CNS penetration effectiveness and protease inhibitor use in multivariate models suggests that protease inhibitors (primarily atazanavir, lopinavir, and ritonavir, in this analysis) might influence the concentration of HIV RNA in CSF by mechanisms that are not adequately described by the CNS penetration-effectiveness method. Although the protease inhibitor effect size was large, the confidence interval of the estimate was broad (OR 3·26, 95% CI 1·04-10·23) and the effect was not selected in models that included a binary transformation of CNS penetration effectiveness (data not shown). If protease inhibitor use were truly clinically associated with increased HIV RNA concentrations in CSF, several explanations would be possible. Protease inhibitors can modulate molecular drug transporters, 25 which could reduce protease inhibitor concentrations in the CNS in a way that is not captured by the CNS penetration-effectiveness method. Consistent with this, some studies have confirmed that CSF concentrations of several protease inhibitors appear to be lower than expected on the basis of the unbound fraction in blood. 26 Protease inhibitors have also recently been linked to cerebral small vessel disease, 27 which could alter drug distribution, adhesion molecule expression, 28 and cell migration. 29 Protease inhibitor use could also be an indicator of unmeasured factors, such as clinical channelling. For example, clinicians tend to choose protease inhibitors for patients who have high HIV RNA concentrations in blood, more advanced immune suppression, increased ART experience, or increased ART drug resistance.
Although our study was large and longitudinal, it does have limitations that could affect the accuracy and interpretation of the findings. The most important is the observational nature of the CHARTER study, meaning that ART initiation was not randomised or synchronised across participants, which can be a source of bias. Another limitation is that the analysis included participants who had detectable HIV RNA in plasma, which could reduce generalisability since suppressing HIV is the chief goal of ART in the clinic. However, most participants who had detectable HIV RNA in plasma had concentrations less than 1000 copies per mL (59·3%), which does not necessarily portend ART failure. 30 Focusing solely on participants taking suppressive ART would require that we re-assay all specimens with a more sensitive assay, such as a single copy assay. Another limitation related to the inclusion of participants who had detectable HIV RNA in plasma is the absence of data for ART drug-resistance mutations in these analyses. The participants were mostly ART-experienced, having previously used a median of five ART drugs. Detectable HIV RNA in CSF could be due to unmeasured ART drug resistance, for example, rather than other factors, such as CNS penetration effectiveness, which could theoretically be colinear with it in analyses of HIV RNA. Finally, by design, this analysis focused on HIV RNA in CSF, not on other neurological outcomes. As noted, we have previously reported links between increased HIV RNA in CSF and two common neurological complications: neurocognitive decline 1 and incident depression. 2 In this large analysis of ART users over the course of up to about 3·5 years, we found that HIV RNA was rarely detectable in CSF (<12% of visits) and that it was associated with several factors over time, most importantly high HIV RNA in plasma. The associations with CD4 cell counts and CSF leucocyte counts are consistent with previous reports, 31 but the association with the concentration of CD8 cells is a new finding that might help identify patients at risk for CSF viral escape and neurological complications. Only two correlates, CNS penetration-effectiveness values and protease inhibitor use, were modifiable, which might have implications for CSF viral escape and achieving functional cure. CHARTER was directly supported by N01 MH22005 and HHSN271201000036C (IG). The work was also supported by R01 MH107345 (R K Heaton and SLL) and K24 MH097673 (SLL). An earlier version of the analyses was presented at the 16th Conference on Retroviruses and Opportunistic Infections. CHARTER is affiliated with
Univariable Multivariable
Change in log 10 HIV RNA concentration in CSF (95% CI) p value Change in log 10 HIV RNA concentration in CSF (95% CI) p value
HIV disease characteristics
Plasma HIV RNA (per 1 log 10 counts per mL) 0·834 (0·464 to 1·204) <0·0001 0·696 (0·364 to 1·029) <0·0001 Current CD4 cell count (per 5 square-root cells per µL) -0·518 (-0·748 to -0·289) <0·0001 -0·0925 (-0·1412 to -0·0438) 0·0002
Treatment characteristics
CPE (per 1 unit) -0·116 (-0.163 to -0·069) <0·0001 -0·0311 (-0·0587 to -0·0035) 0·027
Protease inhibitor use 0·481 (0·248 to 0·714) 0·0001 0·219 (0·0886 to 0·3494) 0·0013
Adherence <95% doses in 4 days before assessment 0·493 (0·288 to 0·697) <0·0001 ·· ·· Number of past antiretrovirals 0·0324 (-0·013 to 0·078) 0·16 ·· ·· Number of current antiretrovirals -0·184 (-0·326 to -0·042) 0·011 ·· ··
Demographics and other characteristics
Age (per 1 year) -0·0261 (-0·047 to -0·005) 0·014 ·· ·· Ethnicity (black) -0·284 (-0·403 to -0·164) <0·0001 0·205 (0·0367 to 0·3733) 0·017
Addictive drug metabolites in urine 0·429 (0·240 to 0·619) <0·0001 0·103 (-0·013 to 0·219) 0·081
Addictive drug use within previous 30 days 0·393 (0·169 to 0·617) 0·0006 ·· ··
CSF characteristics
CSF leucocytes (per 5 cells per µL) 0·0389 (0·0325 to 0·0452) <0·0001 0·0247 (0·0133 to 0·0361) <0·0001 CSF total protein (per 10 mg/L) 0·00916 (0·00479 to 0·01353) <0·0001 0·0025 (-0·0002 to 0·0052) 0·069
CSF=cerebrospinal fluid. CPE=central nervous system penetration effectiveness. Table 3 : Correlates of continuous HIV RNA concentration in CSF accounting for censoring below the lower limit of quantitation
